# Cortex Health — Status Follow-Up
## March 18, 2026

---

## Where We Stand

Over the past session, the Cortex Boardroom C-suite ran a full 3-day strategic summit, produced a 16-risk operational register with complete mitigations, and unified three strategic documents (PRD, MBA Strategy, and Summit outcomes) into a single master execution prompt for the Claude CLI. Here is the state of play.

---

## Codebase Status

The holilabsv2 codebase (Next.js + Prisma + Vue.js) is in a functional but incomplete state:

- **Production build passes** — `pnpm build` exits 0.
- **Test coverage at ~95%** — 4,756 of 4,991 tests pass; 120 failing test suites remain (mostly stale mocks and import path drift from recent refactors).
- **MVP Pilot Launch progress** — Units 1-3 complete (auth, RBAC, core CDSS flows). Unit 4 (test stabilization) is 50% done. Unit 5 (pilot invite flow) has not started.
- **Infrastructure** — DigitalOcean deployment pipeline functional. Sentry monitoring active. PostHog analytics integrated.

The codebase is ready for the Phase 0 stabilization work defined in the master prompt.

---

## Strategic Documents Produced

Three foundational strategy documents now govern all forward execution:

1. **Cortex Boardroom 3-Day Summit** (`cortex-boardroom-summit-march-2026.md`, 51KB) — Full C-suite simulation with all 8 personas. Defined the Cortex Swarm Layer architecture, product surfaces (TLP, CDRM, DAS), GTM strategy, unit economics, and sprint sequencing. Contains 12 formal decisions with owners and veto confirmations.

2. **Risk Register** (`cortex-swarm-layer-risk-register-march-2026.md`, 35KB) — 16 risks identified and classified: 3 Critical, 5 High, 5 Medium, 3 Low. Each risk has severity scoring, ownership, mitigation strategy, and due dates.

3. **Master Execution Prompt** (`CSL-MASTER-PROMPT.md`, 39KB) — The unified CLI execution plan that integrates the PRD, MBA Strategy, and Summit into a single prioritized work sequence across 7 phases (0 through 6) with gate reviews at Months 3, 6, and 12.

---

## Risk Mitigations Completed

All 16 risks from the register have been addressed with dedicated mitigation documents in `risk-mitigation/`:

| # | Risk | Document | Size | Key Outcome |
|---|------|----------|------|-------------|
| 001 | LGPD Cloud GPU Compliance | `RISK-001-lgpd-cloud-gpu-audit.md` | 35KB | AWS sa-east-1 confirmed as primary path; OASIS Alibaba default must be patched |
| 002 | ANVISA SaMD Classification | `RISK-002-anvisa-samd-classification-analysis.md` | 46KB | TLP likely exempt; CDRM borderline Class II; DAS likely Class II-III; Consulta Previa recommended |
| 003 | Re-identification in Small Populations | `RISK-003-reidentification-prevention-spec.md` | 40KB | OpenDP differential privacy with epsilon 1.0; n>=50 hard floor; 4 attack vectors mapped |
| 004 | GPU Compute Cost Overrun | `RISK-004-gpu-compute-vendor-review.md` | 20KB | Hybrid strategy: AWS cloud for pilot, Equinix colocation for production; AWQ 4-bit quantization |
| 005 | Competitive Threat Window | `RISK-005-competitive-intelligence-brief.md` | 35KB | Hippocratic AI ($126M Series C) and Bionexo (2,000 hospitals) identified as primary threats |
| 006 | OASIS Framework Viability | `RISK-006-oasis-framework-adr.md` | 27KB | **Critical pivot: Mesa replaces OASIS** as primary simulation framework (determinism, audit trail) |
| 007 | Pilot Hospital Economics | `RISK-007-pilot-economics-model.md` | 22KB | $10K nominal pilot fee; outcome-linked bonus; board escalation at Month 9 |
| 008 | Simulation Abuse Prevention | `RISK-008-simulation-abuse-prevention.md` | 43KB | 5 attack vectors; strict typed schema; 4-layer output sanitization; DB-level firewall |
| 009 | Clinical Trust Deficit | `RISK-009-clinical-trust-research-plan.md` | 27KB | 3-week research sprint; 12-15 participants; three framings tested |
| 010 | Consent UX Compliance | `RISK-010-consent-ux-specification.md` | 69KB | Full bilingual consent copy; progressive disclosure flow; LGPD compliance briefing |
| 011 | Simulation Determinism | `RISK-011-simulation-determinism-testing-strategy.md` | 41KB | 5-category test suite; temperature 0.0; seed-controlled replay; +/-15% variance threshold |
| 012 | Model Version Drift | `RISK-012-model-versioning-change-management.md` | 32KB | Model pinning policy; 27-39 day update protocol; 4-stakeholder approval gate |
| 013 | Pilot Reputation Risk | `RISK-013-pilot-reputation-runbook.md` | 38KB | Pilot agreement language; amber "PILOT VALIDATION MODE" banner; crisis communication plan |
| 014 | Infrastructure Resilience | `RISK-014-infrastructure-resilience-runbook.md` | 38KB | 4-state graceful degradation; 99.5% SLA; Prometheus + PagerDuty |
| 015 | OASIS License Review | `RISK-015-oasis-license-review.md` | 22KB | OASIS is Apache 2.0 (not MIT); patent grant protects; zero GPL contamination |
| 016 | CI/CD Test Tiering | `RISK-016-ci-test-tiering-strategy.md` | 39KB | 3 tiers: PR (<2 min), merge (<10 min), nightly (60 min); $82-107/month CI cost |

Total mitigation documentation: ~574KB across 16 documents.

---

## Architecture Decision: Mesa Over OASIS

The most consequential finding from the risk assessment was **RISK-006**: OASIS is not production-grade for clinical use. The framework relies on LLM-driven agent logic (non-deterministic), lacks clinical metadata support, and defaults to Chinese-hosted inference endpoints that violate LGPD Art. 33.

The decision: **Mesa** (Python agent-based modeling) is now the primary simulation framework. It offers deterministic execution, 350+ healthcare research papers, rule-based agent logic, and clean audit trails. OASIS concepts (GraphRAG knowledge graphs, multi-agent communication patterns) will be adapted into the Mesa architecture through a framework abstraction layer.

This changes the technical approach but preserves the strategic vision of the Cortex Swarm Layer.

---

## What the Master Prompt Covers

The `CSL-MASTER-PROMPT.md` is ready to feed into a Claude CLI session. It sequences all work across 7 phases:

- **Phase 0** (Immediate) — Stabilize the MVP. Fix the 120 failing test suites, complete the pilot invite flow, harden RBAC.
- **Phase 0.5** (Months 1-3) — Close the three rate-limiting gates: file ANVISA Consulta Previa, build FHIR/HL7 EHR integration layer, begin clinical validation study design.
- **Phase 1** — Mesa simulation framework scaffold with abstraction layer.
- **Phase 2** — Build the three product surfaces: Triage Load Predictor, Cohort Deterioration Risk Map, Drug Adherence Simulation.
- **Phase 3** — Differential privacy, consent UX, LGPD compliance hardening.
- **Phase 4** — Hospital pilot deployment with graceful degradation and monitoring.
- **Phase 5** — Clinical validation, model versioning, competitive moat.
- **Phase 6** (Months 7-12) — Market entry: hospital pilots at scale, operadora partnerships, ANVISA Class II submission, Series A preparation.

Each phase has explicit entry conditions, exit criteria, and cross-references to the PRD requirements (REQ-R01 through REQ-T02), MBA Strategy initiatives, and risk mitigation documents.

---

## Immediate Next Actions (This Week)

1. **Feed `CSL-MASTER-PROMPT.md` to a Claude CLI session** and begin Phase 0 (test stabilization).
2. **Engage ANVISA regulatory counsel** to initiate the Consulta Previa process ($8-12K, 4-week turnaround) per RISK-002.
3. **Contact Philips Tasy** for FHIR sandbox access — this unblocks the EHR integration gate.
4. **Schedule red-team audit vendor calls** for the differential privacy implementation per RISK-003 ($25-50K budget).
5. **Begin LOI outreach** to beachhead hospitals (USP, UNIFESP, Beneficencia Portuguesa) per RISK-005 competitive timeline.

---

## Open Questions Requiring Human Decision

These items from the PRD and MBA Strategy remain unresolved and will block progress at specific gates:

1. **ANVISA classification confirmation** — The Consulta Previa will determine whether TLP, CDRM, and DAS require Class I, II, or III registration. This affects the entire regulatory timeline.
2. **Burn rate and runway** — Current runway figures were not provided. The MBA Strategy's gate review at Month 3 requires a pass/fail on "6+ months runway remaining."
3. **EHR vendor priority** — Philips Tasy, MV Sistemas, and Pixeon each serve different hospital segments. Which vendor should be targeted first for integration?
4. **Clinical validation study PI** — A principal investigator at a beachhead hospital must be identified to lead the 50-100 case study.

---

*This document was produced by the Cortex Boardroom C-suite session on March 18, 2026. All deliverables are located in the holilabsv2 project root and `risk-mitigation/` subdirectory.*
